Global behaviour Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory‐Nursing Home version (NPI‐NH) and Nurses Observations Scale for Geriatric Patients (NOSGER) (lower scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
257 participants
Very low

Whole‐facility changes: Home‐like models vs traditional environment

Depression Revised Memory and Behaviour Problems Checklist (RMBPC) and Mood Scale Score (MSS) (lower scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
406 participants
Very low

Whole‐facility changes: Home‐like models vs traditional environment

Activities of daily living · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
499 participants
Very low

Whole‐facility changes: Home‐like models vs traditional environment

Serious adverse effects Physical restraints, reported as percentage points (lower = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings

It is very uncertain whether whole‐facility changes: Home‐like models changes serious adverse effects Physical restraints, reported as percentage… compared with traditional environment (very low certainty).

1 finding from 1 review

Physical environmental designs in residential care to improve quality of life of older people 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 74449 participants
Very low

Berotralstat vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Berotralstat vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Low

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Lanadelumab vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Lanadelumab vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Cemented vs uncemented hemiarthroplasty

Activities of daily living · adults with displaced and undisplaced hip fractures

1 finding from 1 review

Arthroplasties for hip fracture in adults 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1275 participants
Moderate